- Home
- TLSI vs CATX Comparison
TLSI vs CATX Comparison
Compare TLSI & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- CATX
- Stock Information
- Founded
- TLSI 2010
- CATX 1983
- Country
- TLSI United States
- CATX United States
- Employees
- TLSI N/A
- CATX N/A
- Industry
- TLSI Medical Specialities
- CATX Medical/Dental Instruments
- Sector
- TLSI Health Care
- CATX Health Care
- Exchange
- TLSI Nasdaq
- CATX Nasdaq
- Market Cap
- TLSI 244.3M
- CATX 239.0M
- IPO Year
- TLSI N/A
- CATX N/A
- Fundamental
- Price
- TLSI $6.21
- CATX $2.17
- Analyst Decision
- TLSI Strong Buy
- CATX Strong Buy
- Analyst Count
- TLSI 3
- CATX 10
- Target Price
- TLSI $10.67
- CATX $11.00
- AVG Volume (30 Days)
- TLSI 114.0K
- CATX 1.9M
- Earning Date
- TLSI 11-13-2025
- CATX 11-10-2025
- Dividend Yield
- TLSI N/A
- CATX N/A
- EPS Growth
- TLSI N/A
- CATX N/A
- EPS
- TLSI N/A
- CATX N/A
- Revenue
- TLSI $40,207,000.00
- CATX $1,075,000.00
- Revenue This Year
- TLSI $57.25
- CATX N/A
- Revenue Next Year
- TLSI $54.05
- CATX N/A
- P/E Ratio
- TLSI N/A
- CATX N/A
- Revenue Growth
- TLSI 49.52
- CATX N/A
- 52 Week Low
- TLSI $3.42
- CATX $1.60
- 52 Week High
- TLSI $6.36
- CATX $5.39
- Technical
- Relative Strength Index (RSI)
- TLSI 77.66
- CATX 36.94
- Support Level
- TLSI $3.79
- CATX $1.96
- Resistance Level
- TLSI $4.88
- CATX $2.31
- Average True Range (ATR)
- TLSI 0.47
- CATX 0.20
- MACD
- TLSI 0.17
- CATX 0.04
- Stochastic Oscillator
- TLSI 96.84
- CATX 39.32
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.